Clinical trial
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed…
NCT00003274 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00003274 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery |
| Official title | A Randomized Phase II Trial of a Vaccine Combining Tyrosinase /gp100 Peptides Emulsified With Montanide ISA 51 Alone or With a Block Co-Polymer CRL 1005 or With GM-CSF for Patients With Resected Stages IIA and IIB Melanoma Grant Application Title: MART-1/gp100 Immune Responses to a Melanoma Vaccine |
| Lead sponsor | University of Southern California, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide |
| Enrollment | 48 |
| Start date | Mar 1, 1998 |
| Primary completion | Sep 1, 2001 |
| Completion | Nov 1, 2002 |
| First posted | Mar 22, 2004 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: